<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04853472</url>
  </required_header>
  <id_info>
    <org_study_id>PROTOCOL-1326</org_study_id>
    <nct_id>NCT04853472</nct_id>
  </id_info>
  <brief_title>Menopause Sample Collection</brief_title>
  <official_title>Menopause Sample Collection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SPD Development Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SPD Development Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide daily urine samples from women during early and late stage&#xD;
      peri-menopause as well as post-menopause over the course of three calendar months in order to&#xD;
      maintain the SPD sample bank.&#xD;
&#xD;
      Urine samples will be received in the clinical laboratory and aliquoted into 2.25ml amounts&#xD;
      and stored at -80ËšC until required.&#xD;
&#xD;
      Symptom information will also be recorded to determine whether there are any noticeable&#xD;
      physiological changes that can be related to stage of the menopause.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of daily urine samples collected from women during various stages of the menopause</measure>
    <time_frame>3 months</time_frame>
    <description>Daily urine samples collected</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Menopause Symptom Information</measure>
    <time_frame>3 months</time_frame>
    <description>Daily recording of experience of a range of menopause symptoms</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">151</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Early Stage Peri-Menopause</arm_group_label>
    <description>Mild cycle irregularity over the last 3-6months (minimum), variation of &gt;6 days in length between consecutive cycles including shortened and longer cycles (but not &gt;60 days in length)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late Stage Peri-Menopause</arm_group_label>
    <description>Late stage peri-menopause: Irregular cycles with prolonged periods of amenorrhea &gt;60 days in length (but less than 12 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-Menopause</arm_group_label>
    <description>Greater than 12 months since last menstrual period</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine Samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy female volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Between the ages of 45 and 60 years&#xD;
&#xD;
          -  Suspects they are going through or have been through the menopause&#xD;
&#xD;
          -  Experiencing cycle irregularities:&#xD;
&#xD;
               -  Early Stage Peri-Menopause: Mild cycle irregularity over the last 3-6months&#xD;
                  (minimum), variation of &gt;6 days in length between consecutive cycles including&#xD;
                  shortened and longer cycles (but not &gt;60 days in length)&#xD;
&#xD;
               -  Late stage peri-menopause: Irregular cycles with prolonged periods of amenorrhea&#xD;
                  &gt;60 days in length (but less than 12 months)&#xD;
&#xD;
               -  Post-Menopause: Greater than 12 months since last menstrual period&#xD;
&#xD;
          -  Willing to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of hormone replacement therapy (HRT)&#xD;
&#xD;
          -  Use of hormone contraception&#xD;
&#xD;
          -  Hysterectomy and/or oophorectomy&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Other medical reason for amenorrhea (absence of menstruation)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female only</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raniero Zazzeroni</last_name>
    <role>Study Director</role>
    <affiliation>SPD Development Company</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jackie Boxer</last_name>
    <role>Principal Investigator</role>
    <affiliation>SPD Development Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SPD Development Company Ltd</name>
      <address>
        <city>Bedford</city>
        <state>Bedfordshire</state>
        <zip>MK44 3UP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

